Fort Knox personal page - To The Moon

Fort Knox

Fort Knox

No personal profile

14Follow

0Followers

0Topic

0Badge

01-23 15:20

Really curious to learn what Anta is not a favorite stock. It has Wilson sports? Maybe will get Puma brand within a year.

Anta Sports Products Stock Slips 2.0% in Hong Kong, Underperforms Competitors

01-23 00:21

$Proshares Ultrashort Silver(ZSL)$ not far from absolute bottom, isn't it?

01-06

Cute for Eczema!?

Alumis Shares Surge 90% as Its Skin Disease Drug Meets Main Goal in Late-Stage Trials

2025-10-24

Why would they open an Australian office?

Anthropic to open South Korea office as part of Asia expansion

2025-08-14

With lenient tariffs expected for China, the US economy can be further fueled by abundance of rare earths. 6700 should be within grasp?

2025-03-18

$Byd Company Limited(002594)$

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4200118252877852","uuid":"4200118252877852","gmtCreate":1737017892413,"gmtModify":1737093241550,"name":"Fort Knox","pinyin":"fortknoxfortknox","introduction":"","introductionEn":null,"signature":"","avatar":"https://community-static.tradeup.com/news/3a3a4b7fe5f82f60d536c6ef62532501","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":14,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.01.14","exceedPercentage":"80.49%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.12.04","exceedPercentage":"93.98%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.11.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":10,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":524807839965840,"gmtCreate":1769152839341,"gmtModify":1769153800038,"author":{"id":"4200118252877852","authorId":"4200118252877852","name":"Fort Knox","avatar":"https://community-static.tradeup.com/news/3a3a4b7fe5f82f60d536c6ef62532501","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4200118252877852","idStr":"4200118252877852"},"themes":[],"title":"","htmlText":"Really curious to learn what Anta is not a favorite stock. It has Wilson sports? Maybe will get Puma brand within a year.&nbsp;","listText":"Really curious to learn what Anta is not a favorite stock. It has Wilson sports? Maybe will get Puma brand within a year.&nbsp;","text":"Really curious to learn what Anta is not a favorite stock. It has Wilson sports? Maybe will get Puma brand within a year.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/524807839965840","repostId":"2605466587","repostType":2,"repost":{"id":"2605466587","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1769070720,"share":"https://ttm.financial/m/news/2605466587?lang=en_US&edition=fundamental","pubTime":"2026-01-22 16:32","market":"sh","language":"en","title":"Anta Sports Products Stock Slips 2.0% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2605466587","media":"Dow Jones","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Anta Sports Products Ltd. slid 2.0% to 77.50 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.2% to 26629.96.This was the stock's second consecutive day of losses.Anta Sports Products Ltd. closed 27% short of its 52-week high of HK$106.30, which the company achieved Aug. 27.The stock underperformed when compared to some of its competitors, as Golden Solar New Energy Technology Holdings Ltd. remained unchanged, Xtep International Holdings Ltd. rose 1.4%, and Pou Sheng International Holdings Ltd. remained unchanged.Trading volume totaled 12.6 million shares, compared to the 50-day average of 8.3 million shares.","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  This article was automatically generated by Dow Jones using technology from Automated Insights. \n</p>\n<p>\n     Shares of <a href=\"https://laohu8.com/S/ANPDF\">Anta Sports Products Ltd.</a> slid 2.0% to 77.50 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the <a href=\"https://laohu8.com/S/HSNGF\">Hang Seng</a> Index rising 0.2% to 26629.96. \n</p>\n<p>\n     This was the stock's second consecutive day of losses. \n</p>\n<p>\n     <a href=\"https://laohu8.com/S/ANPDY\">Anta Sports Products</a> Ltd. closed 27% short of its 52-week high of HK$106.30, which the company achieved Aug. 27. \n</p>\n<p>\n     The stock underperformed when compared to some of its competitors, as Golden Solar New Energy Technology Holdings Ltd. remained unchanged, <a href=\"https://laohu8.com/S/XTPEF\">Xtep International Holdings Ltd.</a> rose 1.4%, and <a href=\"https://laohu8.com/S/PSHGY\">Pou Sheng International Holdings Ltd.</a> remained unchanged. \n</p>\n<p>\n     Trading volume totaled 12.6 million shares, compared to the 50-day average of 8.3 million shares. \n</p>\n<p>\n  Data source: Dow Jones Market Data, FactSet \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2026 03:32 ET (08:32 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anta Sports Products Stock Slips 2.0% in Hong Kong, Underperforms Competitors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnta Sports Products Stock Slips 2.0% in Hong Kong, Underperforms Competitors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-22 16:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  This article was automatically generated by Dow Jones using technology from Automated Insights. \n</p>\n<p>\n     Shares of <a href=\"https://laohu8.com/S/ANPDF\">Anta Sports Products Ltd.</a> slid 2.0% to 77.50 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the <a href=\"https://laohu8.com/S/HSNGF\">Hang Seng</a> Index rising 0.2% to 26629.96. \n</p>\n<p>\n     This was the stock's second consecutive day of losses. \n</p>\n<p>\n     <a href=\"https://laohu8.com/S/ANPDY\">Anta Sports Products</a> Ltd. closed 27% short of its 52-week high of HK$106.30, which the company achieved Aug. 27. \n</p>\n<p>\n     The stock underperformed when compared to some of its competitors, as Golden Solar New Energy Technology Holdings Ltd. remained unchanged, <a href=\"https://laohu8.com/S/XTPEF\">Xtep International Holdings Ltd.</a> rose 1.4%, and <a href=\"https://laohu8.com/S/PSHGY\">Pou Sheng International Holdings Ltd.</a> remained unchanged. \n</p>\n<p>\n     Trading volume totaled 12.6 million shares, compared to the 50-day average of 8.3 million shares. \n</p>\n<p>\n  Data source: Dow Jones Market Data, FactSet \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2026 03:32 ET (08:32 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"82020":"安踏体育-R","91348":"深圳市道通科技股份有限公司（临时代码）","LU0823426308.USD":"法巴中国股票基金","BK1589":"北水核心资产","LU0048575426.USD":"FIDELITY EMERGING MARKETS \"A\" INC","BK1500":"做空集合股","LU0261950470.USD":"FIDELITY EMERGING MARKETS \"A\" ACC","IE0008368742.USD":"首域中国增长基金I Acc","LU0594300419.USD":"富达中国消费基金A","LU0650527681.SGD":"Fidelity China Consumer A-SGD","LU0605514214.HKD":"FIDELITY CHINA CONSUMER \"A\" (HKD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0261947096.USD":"FIDELITY FUNDS  SUSTAINABLE ASIA EQUITY \"A\" (USD) ACC","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1831875114.USD":"SCHRODER ISF ALL CHINA EQUITY \"A\" (USD) ACC","LU0594300179.USD":"FIDELITY CHINA CONSUMER \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","IE00B031J352.USD":"FSSA GREATER CHINA GROWTH \"I\" (USD) INC","ANPDY":"安踏体育ADR","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","IE00BGV7N243.SGD":"FSSA Global Emerging Markets Focus I Acc SGD","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","IE0031814852.USD":"FSSA GREATER CHINA GROWTH \"I\" (USD) ACC","BK1512":"体育用品","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","LU0251143458.SGD":"Fidelity Emerging Markets A-SGD","LU0140636845.USD":"施罗德大中华区股票A Acc","IE00BQXX3F31.USD":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","02020":"安踏体育","LU0251144936.SGD":"Fidelity Sustainable Asia Equity A-SGD","BK1168":"鞋类","LU0823426480.USD":"法巴中国股票经典Dis","BK1521":"挪威政府全球养老基金持仓","LU0048597586.USD":"富达亚洲焦点A","BK1502":"双十一","BK1227":"服装、服饰与奢侈品","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV","LU0244354667.USD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" ACC"},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2605466587","content_text":"This article was automatically generated by Dow Jones using technology from Automated Insights. \n\n\n     Shares of Anta Sports Products Ltd. slid 2.0% to 77.50 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.2% to 26629.96. \n\n\n     This was the stock's second consecutive day of losses. \n\n\nAnta Sports Products Ltd. closed 27% short of its 52-week high of HK$106.30, which the company achieved Aug. 27. \n\n\n     The stock underperformed when compared to some of its competitors, as Golden Solar New Energy Technology Holdings Ltd. remained unchanged, Xtep International Holdings Ltd. rose 1.4%, and Pou Sheng International Holdings Ltd. remained unchanged. \n\n\n     Trading volume totaled 12.6 million shares, compared to the 50-day average of 8.3 million shares. \n\n\n  Data source: Dow Jones Market Data, FactSet \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 22, 2026 03:32 ET (08:32 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","news_type":1,"symbols_score_info":{"82020":0.6,"91348":0.89,"ANPDY":0.6,"02020":0.9}},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":524586404054280,"gmtCreate":1769098900186,"gmtModify":1769098903290,"author":{"id":"4200118252877852","authorId":"4200118252877852","name":"Fort Knox","avatar":"https://community-static.tradeup.com/news/3a3a4b7fe5f82f60d536c6ef62532501","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4200118252877852","idStr":"4200118252877852"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/ZSL\">$Proshares Ultrashort Silver(ZSL)$ </a> not far from absolute bottom, isn't it?&nbsp;","listText":"<a href=\"https://ttm.financial/S/ZSL\">$Proshares Ultrashort Silver(ZSL)$ </a> not far from absolute bottom, isn't it?&nbsp;","text":"$Proshares Ultrashort Silver(ZSL)$ not far from absolute bottom, isn't it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/524586404054280","isVote":1,"tweetType":1,"viewCount":8,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":518920998585032,"gmtCreate":1767712614272,"gmtModify":1767713840135,"author":{"id":"4200118252877852","authorId":"4200118252877852","name":"Fort Knox","avatar":"https://community-static.tradeup.com/news/3a3a4b7fe5f82f60d536c6ef62532501","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4200118252877852","idStr":"4200118252877852"},"themes":[],"title":"","htmlText":"Cute for Eczema!?","listText":"Cute for Eczema!?","text":"Cute for Eczema!?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/518920998585032","repostId":"2601892026","repostType":2,"repost":{"id":"2601892026","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1767704755,"share":"https://ttm.financial/m/news/2601892026?lang=en_US&edition=fundamental","pubTime":"2026-01-06 21:05","market":"us","language":"en","title":"Alumis Shares Surge 90% as Its Skin Disease Drug Meets Main Goal in Late-Stage Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2601892026","media":"Reuters","summary":"$Alumis(ALMS)$ said on Tuesday its experimental drug to treat a common skin disease met the main goal in two late-stage studies, offering hope for a new oral treatment option that affects millions of...","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/ALMS\">Alumis</a> said on Tuesday its experimental drug to treat a common skin disease met the main goal in two late-stage studies, offering hope for a new oral treatment option that affects millions of Americans.</p><p>Shares of the South San Francisco-based company soared about 90% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/e52448eb1c0b1054f5ea8310f82ac423\" tg-width=\"837\" tg-height=\"615\"/></p><p>The drug, envudeucitinib, is being developed to treat moderate-to-severe plaque psoriasis, a chronic condition that causes red, scaly patches on the skin. Over 8 million people in the U.S. have psoriasis, according to the National Psoriasis Foundation.</p><p>In the trials, about 65% of patients saw their skin symptoms improve by 90% or more after 24 weeks of treatment. More than 40% of patients saw their symptoms clear up completely, the company said.</p><p>The drug also worked better than a placebo and outperformed Amgen&#39;s AMGN.O oral drug Otezla, Alumis added.</p><p>Leerink Partners analyst Thomas Smith said the drug offers &#34;potential for class-leading TYK2 inhibition&#34; and effectiveness approaching that of top-selling injectable drugs.</p><p>Envudeucitinib works by blocking TYK2, a protein that helps trigger immune signals linked to inflammation. This reduces the overactive immune response that causes psoriasis.</p><p>The company plans to seek U.S. regulatory approval for envudeucitinib in the second half of 2026. If cleared, it would compete with Bristol Myers Squibb&#39;s BMY.N Sotyktu, another drug in the same class approved for psoriasis in 2022.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alumis Shares Surge 90% as Its Skin Disease Drug Meets Main Goal in Late-Stage Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlumis Shares Surge 90% as Its Skin Disease Drug Meets Main Goal in Late-Stage Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-06 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/ALMS\">Alumis</a> said on Tuesday its experimental drug to treat a common skin disease met the main goal in two late-stage studies, offering hope for a new oral treatment option that affects millions of Americans.</p><p>Shares of the South San Francisco-based company soared about 90% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/e52448eb1c0b1054f5ea8310f82ac423\" tg-width=\"837\" tg-height=\"615\"/></p><p>The drug, envudeucitinib, is being developed to treat moderate-to-severe plaque psoriasis, a chronic condition that causes red, scaly patches on the skin. Over 8 million people in the U.S. have psoriasis, according to the National Psoriasis Foundation.</p><p>In the trials, about 65% of patients saw their skin symptoms improve by 90% or more after 24 weeks of treatment. More than 40% of patients saw their symptoms clear up completely, the company said.</p><p>The drug also worked better than a placebo and outperformed Amgen&#39;s AMGN.O oral drug Otezla, Alumis added.</p><p>Leerink Partners analyst Thomas Smith said the drug offers &#34;potential for class-leading TYK2 inhibition&#34; and effectiveness approaching that of top-selling injectable drugs.</p><p>Envudeucitinib works by blocking TYK2, a protein that helps trigger immune signals linked to inflammation. This reduces the overactive immune response that causes psoriasis.</p><p>The company plans to seek U.S. regulatory approval for envudeucitinib in the second half of 2026. If cleared, it would compete with Bristol Myers Squibb&#39;s BMY.N Sotyktu, another drug in the same class approved for psoriasis in 2022.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","BK4559":"巴菲特持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","BK4588":"碎股","ALMS":"Alumis Inc.","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4007":"制药","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","BK4585":"ETF&股票定投概念"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL4N3Y70Q5:2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2601892026","content_text":"Alumis said on Tuesday its experimental drug to treat a common skin disease met the main goal in two late-stage studies, offering hope for a new oral treatment option that affects millions of Americans.Shares of the South San Francisco-based company soared about 90% in premarket trading.The drug, envudeucitinib, is being developed to treat moderate-to-severe plaque psoriasis, a chronic condition that causes red, scaly patches on the skin. Over 8 million people in the U.S. have psoriasis, according to the National Psoriasis Foundation.In the trials, about 65% of patients saw their skin symptoms improve by 90% or more after 24 weeks of treatment. More than 40% of patients saw their symptoms clear up completely, the company said.The drug also worked better than a placebo and outperformed Amgen's AMGN.O oral drug Otezla, Alumis added.Leerink Partners analyst Thomas Smith said the drug offers \"potential for class-leading TYK2 inhibition\" and effectiveness approaching that of top-selling injectable drugs.Envudeucitinib works by blocking TYK2, a protein that helps trigger immune signals linked to inflammation. This reduces the overactive immune response that causes psoriasis.The company plans to seek U.S. regulatory approval for envudeucitinib in the second half of 2026. If cleared, it would compete with Bristol Myers Squibb's BMY.N Sotyktu, another drug in the same class approved for psoriasis in 2022.","news_type":1,"symbols_score_info":{"ALMS":0.9}},"isVote":1,"tweetType":1,"viewCount":125,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":492505269276792,"gmtCreate":1761263196277,"gmtModify":1761269623174,"author":{"id":"4200118252877852","authorId":"4200118252877852","name":"Fort Knox","avatar":"https://community-static.tradeup.com/news/3a3a4b7fe5f82f60d536c6ef62532501","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4200118252877852","idStr":"4200118252877852"},"themes":[],"htmlText":"Why would they open an Australian office?","listText":"Why would they open an Australian office?","text":"Why would they open an Australian office?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/492505269276792","repostId":"2577055883","repostType":2,"repost":{"id":"2577055883","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1761260400,"share":"https://ttm.financial/m/news/2577055883?lang=en_US&edition=fundamental","pubTime":"2025-10-24 07:00","market":"fut","language":"en","title":"Anthropic to open South Korea office as part of Asia expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2577055883","media":"Reuters","summary":"SINGAPORE Oct 24 - Artificial intelligence startup Anthropic will open an office in South Korea, as it ramps up its Asia expansion, a top executive said on Thursday.“Out of the top five  users globally, three are in Asia: Korea, Japan, and India,” Chief Commercial Officer Paul Smith told Reuters in an interview. He said that 25% of the overall usage of its AI coding tool, Claude Code, happens in Asia, with the most active user being in South Korea. The company said the number of Claude Code active weekly users in Korea had grown sixfold in the last four months.The move comes on the heels of a large-scale global expansion by Anthropic to triple its international workforce to meet a rise in demand for its Claude AI large language models outside the United States.“That growth is going to accelerate in 2026,” Smith said. “We’re focused on the enterprise business and we’re now just approaching $7 billion of revenue,\" referring to the company's annualized revenue run rate.","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Anthropic to open South Korea office as part of Asia expansion</title></head><body><p>\n<span>SINGAPORE Oct 24</span><span> - </span>Artificial intelligence startup Anthropic will open an office in South Korea, as it ramps up its Asia expansion, a top executive said on Thursday.</p><p>“Out of the top five (Anthropic) users globally, three are in Asia: Korea, Japan, and India,” Chief Commercial Officer Paul Smith told Reuters in an interview. </p><p>He said that 25% of the overall usage of its AI coding tool, Claude Code, happens in Asia, with the most active user being in South Korea. The company said the number of Claude Code active weekly users in Korea had grown sixfold in the last four months.</p><p>The move comes on the heels of a large-scale global expansion by Anthropic to triple its international workforce to meet a rise in demand for its Claude AI <span>large language </span>models outside the United States.</p><p>“That growth is going to accelerate in 2026,” Smith said. “We’re focused on the enterprise business and we’re now just approaching $7 billion of revenue,\" referring to the company's annualized revenue run rate.</p><p>\n<span>The AI startup is racing rivals to build models that can reliably operate software and complete multi-step work, key for AI agents, which can perform tasks on behalf of humans.</span>\n</p><p>Anthropic’s AI model Claude now has more than 300,000 enterprise customers, with nearly 80% of usage coming from outside the U.S.</p><p>Smith said the startup will open its Seoul office in early 2026, while already providing services to partners like <a href=\"https://laohu8.com/S/SKMTF\">SK Telecom</a>, which invested $100 million in the startup in 2023.</p><p>The Alphabet &lt;GOOGL.O&gt; and <a href=\"https://laohu8.com/S/AMZN\">Amazon</a>.com-backed &lt;<span>A</span>MZN.O&gt; AI firm, <span>valued at $183 billion</span>, already announced plans to open offices in Tokyo and the Indian tech hub of Bengaluru and is hiring for over 100 roles in Dublin, London, and Zurich.</p><p>The executive told Reuters that Anthropic is searching for local partners in all three Asian markets to support clients and that a further expansion is expected to include an office in Australia.</p><p> (Reporting by Fanny Potkin in Singapore; Editing by Aurora Ellis)</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anthropic to open South Korea office as part of Asia expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnthropic to open South Korea office as part of Asia expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-24 07:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Anthropic to open South Korea office as part of Asia expansion</title></head><body><p>\n<span>SINGAPORE Oct 24</span><span> - </span>Artificial intelligence startup Anthropic will open an office in South Korea, as it ramps up its Asia expansion, a top executive said on Thursday.</p><p>“Out of the top five (Anthropic) users globally, three are in Asia: Korea, Japan, and India,” Chief Commercial Officer Paul Smith told Reuters in an interview. </p><p>He said that 25% of the overall usage of its AI coding tool, Claude Code, happens in Asia, with the most active user being in South Korea. The company said the number of Claude Code active weekly users in Korea had grown sixfold in the last four months.</p><p>The move comes on the heels of a large-scale global expansion by Anthropic to triple its international workforce to meet a rise in demand for its Claude AI <span>large language </span>models outside the United States.</p><p>“That growth is going to accelerate in 2026,” Smith said. “We’re focused on the enterprise business and we’re now just approaching $7 billion of revenue,\" referring to the company's annualized revenue run rate.</p><p>\n<span>The AI startup is racing rivals to build models that can reliably operate software and complete multi-step work, key for AI agents, which can perform tasks on behalf of humans.</span>\n</p><p>Anthropic’s AI model Claude now has more than 300,000 enterprise customers, with nearly 80% of usage coming from outside the U.S.</p><p>Smith said the startup will open its Seoul office in early 2026, while already providing services to partners like <a href=\"https://laohu8.com/S/SKMTF\">SK Telecom</a>, which invested $100 million in the startup in 2023.</p><p>The Alphabet &lt;GOOGL.O&gt; and <a href=\"https://laohu8.com/S/AMZN\">Amazon</a>.com-backed &lt;<span>A</span>MZN.O&gt; AI firm, <span>valued at $183 billion</span>, already announced plans to open offices in Tokyo and the Indian tech hub of Bengaluru and is hiring for over 100 roles in Dublin, London, and Zurich.</p><p>The executive told Reuters that Anthropic is searching for local partners in all three Asian markets to support clients and that a further expansion is expected to include an office in Australia.</p><p> (Reporting by Fanny Potkin in Singapore; Editing by Aurora Ellis)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU0096362180.USD":"CT (LUX) I GLOBAL FOCUS \"DU\" (USD)","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU0342679015.USD":"ALLIANZ GLOBAL EQUITY UNCONSTRAINED \"AT\" (USD) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU0080751232.USD":"富达环球多元动力基金A","LU0444971666.USD":"天利全球科技基金","LU0061474705.USD":"THREADNEEDLE (LUX) GLOBAL DYNAMIC REAL RETURN \"AU\" (USD) ACC","LU0289941410.SGD":"AB FCP I Dynamic Diversified AX SGD","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","LU2381873111.SGD":"BGF SYSTEMATIC GLOBAL EQUITY HIGH INCOME \"A6\" (SGDHDG) INC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0215105999.USD":"SCHRODER ISF GLOBAL EQUITY \"A\" ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","BK4585":"ETF&股票定投概念","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU2247934214.USD":"FIDELITY FUNDS SUSTAINABLE FUTURE CONNECTIVITY \"A\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","BK4503":"景林资产持仓","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU2092937148.SGD":"Blackrock ESG Multi-Asset A8 SGD-H","LU0109392836.USD":"富兰克林科技股A","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2092627202.USD":"Blackrock ESG Multi-Asset A8 USD-H","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU0302445910.USD":"SCHRODER ISF GLOBAL CLIMATE CHANGE EQUITY \"A\" ACC","LU2077746001.SGD":"Blackrock ESG Multi-Asset A2 SGD-H","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU1935043023.USD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME \"AA\" (USD) INC A","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","USAW.SI":"AMZN 3xLongSG261006","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","SG9999014906.USD":"大华全球优质成长基金Acc USD"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nL6N3W40WY:2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2577055883","content_text":"Anthropic to open South Korea office as part of Asia expansion\nSINGAPORE Oct 24 - Artificial intelligence startup Anthropic will open an office in South Korea, as it ramps up its Asia expansion, a top executive said on Thursday.“Out of the top five (Anthropic) users globally, three are in Asia: Korea, Japan, and India,” Chief Commercial Officer Paul Smith told Reuters in an interview. He said that 25% of the overall usage of its AI coding tool, Claude Code, happens in Asia, with the most active user being in South Korea. The company said the number of Claude Code active weekly users in Korea had grown sixfold in the last four months.The move comes on the heels of a large-scale global expansion by Anthropic to triple its international workforce to meet a rise in demand for its Claude AI large language models outside the United States.“That growth is going to accelerate in 2026,” Smith said. “We’re focused on the enterprise business and we’re now just approaching $7 billion of revenue,\" referring to the company's annualized revenue run rate.\nThe AI startup is racing rivals to build models that can reliably operate software and complete multi-step work, key for AI agents, which can perform tasks on behalf of humans.\nAnthropic’s AI model Claude now has more than 300,000 enterprise customers, with nearly 80% of usage coming from outside the U.S.Smith said the startup will open its Seoul office in early 2026, while already providing services to partners like SK Telecom, which invested $100 million in the startup in 2023.The Alphabet <GOOGL.O> and Amazon.com-backed <AMZN.O> AI firm, valued at $183 billion, already announced plans to open offices in Tokyo and the Indian tech hub of Bengaluru and is hiring for over 100 roles in Dublin, London, and Zurich.The executive told Reuters that Anthropic is searching for local partners in all three Asian markets to support clients and that a further expansion is expected to include an office in Australia. (Reporting by Fanny Potkin in Singapore; Editing by Aurora Ellis)","news_type":1,"symbols_score_info":{"USAW.SI":0.6}},"isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":467449181118760,"gmtCreate":1755161081432,"gmtModify":1755164106319,"author":{"id":"4200118252877852","authorId":"4200118252877852","name":"Fort Knox","avatar":"https://community-static.tradeup.com/news/3a3a4b7fe5f82f60d536c6ef62532501","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4200118252877852","idStr":"4200118252877852"},"themes":[],"htmlText":"With lenient tariffs expected for China, the US economy can be further fueled by abundance of rare earths. 6700 should be within grasp?","listText":"With lenient tariffs expected for China, the US economy can be further fueled by abundance of rare earths. 6700 should be within grasp?","text":"With lenient tariffs expected for China, the US economy can be further fueled by abundance of rare earths. 6700 should be within grasp?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/467449181118760","isVote":1,"tweetType":1,"viewCount":201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":414872013340736,"gmtCreate":1742311359777,"gmtModify":1742314654700,"author":{"id":"4200118252877852","authorId":"4200118252877852","name":"Fort Knox","avatar":"https://community-static.tradeup.com/news/3a3a4b7fe5f82f60d536c6ef62532501","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4200118252877852","idStr":"4200118252877852"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/002594\">$Byd Company Limited(002594)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/002594\">$Byd Company Limited(002594)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$Byd Company Limited(002594)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/414872013340736","isVote":1,"tweetType":1,"viewCount":273,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":524807839965840,"gmtCreate":1769152839341,"gmtModify":1769153800038,"author":{"id":"4200118252877852","authorId":"4200118252877852","name":"Fort Knox","avatar":"https://community-static.tradeup.com/news/3a3a4b7fe5f82f60d536c6ef62532501","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4200118252877852","authorIdStr":"4200118252877852"},"themes":[],"title":"","htmlText":"Really curious to learn what Anta is not a favorite stock. It has Wilson sports? Maybe will get Puma brand within a year.&nbsp;","listText":"Really curious to learn what Anta is not a favorite stock. It has Wilson sports? Maybe will get Puma brand within a year.&nbsp;","text":"Really curious to learn what Anta is not a favorite stock. It has Wilson sports? Maybe will get Puma brand within a year.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/524807839965840","repostId":"2605466587","repostType":2,"repost":{"id":"2605466587","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1769070720,"share":"https://ttm.financial/m/news/2605466587?lang=en_US&edition=fundamental","pubTime":"2026-01-22 16:32","market":"sh","language":"en","title":"Anta Sports Products Stock Slips 2.0% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2605466587","media":"Dow Jones","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Anta Sports Products Ltd. slid 2.0% to 77.50 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.2% to 26629.96.This was the stock's second consecutive day of losses.Anta Sports Products Ltd. closed 27% short of its 52-week high of HK$106.30, which the company achieved Aug. 27.The stock underperformed when compared to some of its competitors, as Golden Solar New Energy Technology Holdings Ltd. remained unchanged, Xtep International Holdings Ltd. rose 1.4%, and Pou Sheng International Holdings Ltd. remained unchanged.Trading volume totaled 12.6 million shares, compared to the 50-day average of 8.3 million shares.","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  This article was automatically generated by Dow Jones using technology from Automated Insights. \n</p>\n<p>\n     Shares of <a href=\"https://laohu8.com/S/ANPDF\">Anta Sports Products Ltd.</a> slid 2.0% to 77.50 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the <a href=\"https://laohu8.com/S/HSNGF\">Hang Seng</a> Index rising 0.2% to 26629.96. \n</p>\n<p>\n     This was the stock's second consecutive day of losses. \n</p>\n<p>\n     <a href=\"https://laohu8.com/S/ANPDY\">Anta Sports Products</a> Ltd. closed 27% short of its 52-week high of HK$106.30, which the company achieved Aug. 27. \n</p>\n<p>\n     The stock underperformed when compared to some of its competitors, as Golden Solar New Energy Technology Holdings Ltd. remained unchanged, <a href=\"https://laohu8.com/S/XTPEF\">Xtep International Holdings Ltd.</a> rose 1.4%, and <a href=\"https://laohu8.com/S/PSHGY\">Pou Sheng International Holdings Ltd.</a> remained unchanged. \n</p>\n<p>\n     Trading volume totaled 12.6 million shares, compared to the 50-day average of 8.3 million shares. \n</p>\n<p>\n  Data source: Dow Jones Market Data, FactSet \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2026 03:32 ET (08:32 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anta Sports Products Stock Slips 2.0% in Hong Kong, Underperforms Competitors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnta Sports Products Stock Slips 2.0% in Hong Kong, Underperforms Competitors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-22 16:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  This article was automatically generated by Dow Jones using technology from Automated Insights. \n</p>\n<p>\n     Shares of <a href=\"https://laohu8.com/S/ANPDF\">Anta Sports Products Ltd.</a> slid 2.0% to 77.50 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the <a href=\"https://laohu8.com/S/HSNGF\">Hang Seng</a> Index rising 0.2% to 26629.96. \n</p>\n<p>\n     This was the stock's second consecutive day of losses. \n</p>\n<p>\n     <a href=\"https://laohu8.com/S/ANPDY\">Anta Sports Products</a> Ltd. closed 27% short of its 52-week high of HK$106.30, which the company achieved Aug. 27. \n</p>\n<p>\n     The stock underperformed when compared to some of its competitors, as Golden Solar New Energy Technology Holdings Ltd. remained unchanged, <a href=\"https://laohu8.com/S/XTPEF\">Xtep International Holdings Ltd.</a> rose 1.4%, and <a href=\"https://laohu8.com/S/PSHGY\">Pou Sheng International Holdings Ltd.</a> remained unchanged. \n</p>\n<p>\n     Trading volume totaled 12.6 million shares, compared to the 50-day average of 8.3 million shares. \n</p>\n<p>\n  Data source: Dow Jones Market Data, FactSet \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2026 03:32 ET (08:32 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"82020":"安踏体育-R","91348":"深圳市道通科技股份有限公司（临时代码）","LU0823426308.USD":"法巴中国股票基金","BK1589":"北水核心资产","LU0048575426.USD":"FIDELITY EMERGING MARKETS \"A\" INC","BK1500":"做空集合股","LU0261950470.USD":"FIDELITY EMERGING MARKETS \"A\" ACC","IE0008368742.USD":"首域中国增长基金I Acc","LU0594300419.USD":"富达中国消费基金A","LU0650527681.SGD":"Fidelity China Consumer A-SGD","LU0605514214.HKD":"FIDELITY CHINA CONSUMER \"A\" (HKD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0261947096.USD":"FIDELITY FUNDS  SUSTAINABLE ASIA EQUITY \"A\" (USD) ACC","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1831875114.USD":"SCHRODER ISF ALL CHINA EQUITY \"A\" (USD) ACC","LU0594300179.USD":"FIDELITY CHINA CONSUMER \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","IE00B031J352.USD":"FSSA GREATER CHINA GROWTH \"I\" (USD) INC","ANPDY":"安踏体育ADR","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","IE00BGV7N243.SGD":"FSSA Global Emerging Markets Focus I Acc SGD","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","IE0031814852.USD":"FSSA GREATER CHINA GROWTH \"I\" (USD) ACC","BK1512":"体育用品","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","LU0251143458.SGD":"Fidelity Emerging Markets A-SGD","LU0140636845.USD":"施罗德大中华区股票A Acc","IE00BQXX3F31.USD":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","02020":"安踏体育","LU0251144936.SGD":"Fidelity Sustainable Asia Equity A-SGD","BK1168":"鞋类","LU0823426480.USD":"法巴中国股票经典Dis","BK1521":"挪威政府全球养老基金持仓","LU0048597586.USD":"富达亚洲焦点A","BK1502":"双十一","BK1227":"服装、服饰与奢侈品","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV","LU0244354667.USD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" ACC"},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2605466587","content_text":"This article was automatically generated by Dow Jones using technology from Automated Insights. \n\n\n     Shares of Anta Sports Products Ltd. slid 2.0% to 77.50 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.2% to 26629.96. \n\n\n     This was the stock's second consecutive day of losses. \n\n\nAnta Sports Products Ltd. closed 27% short of its 52-week high of HK$106.30, which the company achieved Aug. 27. \n\n\n     The stock underperformed when compared to some of its competitors, as Golden Solar New Energy Technology Holdings Ltd. remained unchanged, Xtep International Holdings Ltd. rose 1.4%, and Pou Sheng International Holdings Ltd. remained unchanged. \n\n\n     Trading volume totaled 12.6 million shares, compared to the 50-day average of 8.3 million shares. \n\n\n  Data source: Dow Jones Market Data, FactSet \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 22, 2026 03:32 ET (08:32 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","news_type":1,"symbols_score_info":{"82020":0.6,"91348":0.89,"ANPDY":0.6,"02020":0.9}},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":524586404054280,"gmtCreate":1769098900186,"gmtModify":1769098903290,"author":{"id":"4200118252877852","authorId":"4200118252877852","name":"Fort Knox","avatar":"https://community-static.tradeup.com/news/3a3a4b7fe5f82f60d536c6ef62532501","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4200118252877852","authorIdStr":"4200118252877852"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/ZSL\">$Proshares Ultrashort Silver(ZSL)$ </a> not far from absolute bottom, isn't it?&nbsp;","listText":"<a href=\"https://ttm.financial/S/ZSL\">$Proshares Ultrashort Silver(ZSL)$ </a> not far from absolute bottom, isn't it?&nbsp;","text":"$Proshares Ultrashort Silver(ZSL)$ not far from absolute bottom, isn't it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/524586404054280","isVote":1,"tweetType":1,"viewCount":8,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":518920998585032,"gmtCreate":1767712614272,"gmtModify":1767713840135,"author":{"id":"4200118252877852","authorId":"4200118252877852","name":"Fort Knox","avatar":"https://community-static.tradeup.com/news/3a3a4b7fe5f82f60d536c6ef62532501","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4200118252877852","authorIdStr":"4200118252877852"},"themes":[],"title":"","htmlText":"Cute for Eczema!?","listText":"Cute for Eczema!?","text":"Cute for Eczema!?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/518920998585032","repostId":"2601892026","repostType":2,"repost":{"id":"2601892026","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1767704755,"share":"https://ttm.financial/m/news/2601892026?lang=en_US&edition=fundamental","pubTime":"2026-01-06 21:05","market":"us","language":"en","title":"Alumis Shares Surge 90% as Its Skin Disease Drug Meets Main Goal in Late-Stage Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2601892026","media":"Reuters","summary":"$Alumis(ALMS)$ said on Tuesday its experimental drug to treat a common skin disease met the main goal in two late-stage studies, offering hope for a new oral treatment option that affects millions of...","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/ALMS\">Alumis</a> said on Tuesday its experimental drug to treat a common skin disease met the main goal in two late-stage studies, offering hope for a new oral treatment option that affects millions of Americans.</p><p>Shares of the South San Francisco-based company soared about 90% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/e52448eb1c0b1054f5ea8310f82ac423\" tg-width=\"837\" tg-height=\"615\"/></p><p>The drug, envudeucitinib, is being developed to treat moderate-to-severe plaque psoriasis, a chronic condition that causes red, scaly patches on the skin. Over 8 million people in the U.S. have psoriasis, according to the National Psoriasis Foundation.</p><p>In the trials, about 65% of patients saw their skin symptoms improve by 90% or more after 24 weeks of treatment. More than 40% of patients saw their symptoms clear up completely, the company said.</p><p>The drug also worked better than a placebo and outperformed Amgen&#39;s AMGN.O oral drug Otezla, Alumis added.</p><p>Leerink Partners analyst Thomas Smith said the drug offers &#34;potential for class-leading TYK2 inhibition&#34; and effectiveness approaching that of top-selling injectable drugs.</p><p>Envudeucitinib works by blocking TYK2, a protein that helps trigger immune signals linked to inflammation. This reduces the overactive immune response that causes psoriasis.</p><p>The company plans to seek U.S. regulatory approval for envudeucitinib in the second half of 2026. If cleared, it would compete with Bristol Myers Squibb&#39;s BMY.N Sotyktu, another drug in the same class approved for psoriasis in 2022.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alumis Shares Surge 90% as Its Skin Disease Drug Meets Main Goal in Late-Stage Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlumis Shares Surge 90% as Its Skin Disease Drug Meets Main Goal in Late-Stage Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-06 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/ALMS\">Alumis</a> said on Tuesday its experimental drug to treat a common skin disease met the main goal in two late-stage studies, offering hope for a new oral treatment option that affects millions of Americans.</p><p>Shares of the South San Francisco-based company soared about 90% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/e52448eb1c0b1054f5ea8310f82ac423\" tg-width=\"837\" tg-height=\"615\"/></p><p>The drug, envudeucitinib, is being developed to treat moderate-to-severe plaque psoriasis, a chronic condition that causes red, scaly patches on the skin. Over 8 million people in the U.S. have psoriasis, according to the National Psoriasis Foundation.</p><p>In the trials, about 65% of patients saw their skin symptoms improve by 90% or more after 24 weeks of treatment. More than 40% of patients saw their symptoms clear up completely, the company said.</p><p>The drug also worked better than a placebo and outperformed Amgen&#39;s AMGN.O oral drug Otezla, Alumis added.</p><p>Leerink Partners analyst Thomas Smith said the drug offers &#34;potential for class-leading TYK2 inhibition&#34; and effectiveness approaching that of top-selling injectable drugs.</p><p>Envudeucitinib works by blocking TYK2, a protein that helps trigger immune signals linked to inflammation. This reduces the overactive immune response that causes psoriasis.</p><p>The company plans to seek U.S. regulatory approval for envudeucitinib in the second half of 2026. If cleared, it would compete with Bristol Myers Squibb&#39;s BMY.N Sotyktu, another drug in the same class approved for psoriasis in 2022.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","BK4559":"巴菲特持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","BK4588":"碎股","ALMS":"Alumis Inc.","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4007":"制药","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","BK4585":"ETF&股票定投概念"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL4N3Y70Q5:2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2601892026","content_text":"Alumis said on Tuesday its experimental drug to treat a common skin disease met the main goal in two late-stage studies, offering hope for a new oral treatment option that affects millions of Americans.Shares of the South San Francisco-based company soared about 90% in premarket trading.The drug, envudeucitinib, is being developed to treat moderate-to-severe plaque psoriasis, a chronic condition that causes red, scaly patches on the skin. Over 8 million people in the U.S. have psoriasis, according to the National Psoriasis Foundation.In the trials, about 65% of patients saw their skin symptoms improve by 90% or more after 24 weeks of treatment. More than 40% of patients saw their symptoms clear up completely, the company said.The drug also worked better than a placebo and outperformed Amgen's AMGN.O oral drug Otezla, Alumis added.Leerink Partners analyst Thomas Smith said the drug offers \"potential for class-leading TYK2 inhibition\" and effectiveness approaching that of top-selling injectable drugs.Envudeucitinib works by blocking TYK2, a protein that helps trigger immune signals linked to inflammation. This reduces the overactive immune response that causes psoriasis.The company plans to seek U.S. regulatory approval for envudeucitinib in the second half of 2026. If cleared, it would compete with Bristol Myers Squibb's BMY.N Sotyktu, another drug in the same class approved for psoriasis in 2022.","news_type":1,"symbols_score_info":{"ALMS":0.9}},"isVote":1,"tweetType":1,"viewCount":125,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":492505269276792,"gmtCreate":1761263196277,"gmtModify":1761269623174,"author":{"id":"4200118252877852","authorId":"4200118252877852","name":"Fort Knox","avatar":"https://community-static.tradeup.com/news/3a3a4b7fe5f82f60d536c6ef62532501","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4200118252877852","authorIdStr":"4200118252877852"},"themes":[],"htmlText":"Why would they open an Australian office?","listText":"Why would they open an Australian office?","text":"Why would they open an Australian office?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/492505269276792","repostId":"2577055883","repostType":2,"isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":467449181118760,"gmtCreate":1755161081432,"gmtModify":1755164106319,"author":{"id":"4200118252877852","authorId":"4200118252877852","name":"Fort Knox","avatar":"https://community-static.tradeup.com/news/3a3a4b7fe5f82f60d536c6ef62532501","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4200118252877852","authorIdStr":"4200118252877852"},"themes":[],"htmlText":"With lenient tariffs expected for China, the US economy can be further fueled by abundance of rare earths. 6700 should be within grasp?","listText":"With lenient tariffs expected for China, the US economy can be further fueled by abundance of rare earths. 6700 should be within grasp?","text":"With lenient tariffs expected for China, the US economy can be further fueled by abundance of rare earths. 6700 should be within grasp?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/467449181118760","isVote":1,"tweetType":1,"viewCount":201,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":414872013340736,"gmtCreate":1742311359777,"gmtModify":1742314654700,"author":{"id":"4200118252877852","authorId":"4200118252877852","name":"Fort Knox","avatar":"https://community-static.tradeup.com/news/3a3a4b7fe5f82f60d536c6ef62532501","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4200118252877852","authorIdStr":"4200118252877852"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/002594\">$Byd Company Limited(002594)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/002594\">$Byd Company Limited(002594)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$Byd Company Limited(002594)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/414872013340736","isVote":1,"tweetType":1,"viewCount":273,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}